# Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer

> **NCT00004132** · PHASE2 · COMPLETED · sponsor: **Jonsson Comprehensive Cancer Center**

## Conditions studied

- Drug/Agent Toxicity by Tissue/Organ
- Leukemia
- Lymphoma
- Multiple Myeloma and Plasma Cell Neoplasm
- Oral Complications
- Radiation Toxicity

## Interventions

- **BIOLOGICAL:** filgrastim
- **BIOLOGICAL:** palifermin
- **DRUG:** cyclophosphamide
- **DRUG:** etoposide
- **DRUG:** ifosfamide
- **PROCEDURE:** quality-of-life assessment
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00004132
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-01
- **Primary completion:** —
- **Final completion:** 2004-05
- **Target enrollment:** — (—)
- **Last updated:** 2013-06-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004132, "Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00004132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*